Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.
Kanjanapan Y, Day D, Butler MO, Wang L, Joshua AM, Hogg D, Leighl NB, Razak ARA, Hansen AR, Boujos S, Chappell M, Chow K, Sherwin B, Stayner LA, Soultani L, Zambrana A, Siu LL, Bedard PL, Spreafico A. Kanjanapan Y, et al. Among authors: leighl nb. Eur J Cancer. 2019 Jan;107:1-7. doi: 10.1016/j.ejca.2018.10.017. Epub 2018 Dec 7. Eur J Cancer. 2019. PMID: 30529898
Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer.
Brade A, Bezjak A, MacRae R, Laurie S, Sun A, Cho J, Leighl N, Pearson S, Southwood B, Wang L, McGill S, Iscoe N, Shepherd FA. Brade A, et al. Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1395-401. doi: 10.1016/j.ijrobp.2010.01.014. Epub 2010 Jun 3. Int J Radiat Oncol Biol Phys. 2011. PMID: 20605367 Clinical Trial.
A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours.
Diaz-Padilla I, Siu LL, San Pedro-Salcedo M, Razak AR, Colevas AD, Shepherd FA, Leighl NB, Neal JW, Thibault A, Liu L, Lisano J, Gao B, Lawson EB, Wakelee HA. Diaz-Padilla I, et al. Among authors: leighl nb. Br J Cancer. 2012 Aug 7;107(4):604-11. doi: 10.1038/bjc.2012.319. Epub 2012 Jul 17. Br J Cancer. 2012. PMID: 22805331 Free PMC article. Clinical Trial.
Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study.
Puts MT, Sattar S, McWatters K, Lee K, Kulik M, MacDonald ME, Jang R, Amir E, Krzyzanowska MK, Leighl N, Fitch M, Joshua AM, Warde P, Tourangeau AE, Alibhai SM. Puts MT, et al. Support Care Cancer. 2017 Mar;25(3):879-886. doi: 10.1007/s00520-016-3476-8. Epub 2016 Nov 9. Support Care Cancer. 2017. PMID: 27830393 Free PMC article.
Sensitive tumour detection and classification using plasma cell-free DNA methylomes.
Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, Zuzarte PC, Borgida A, Wang TT, Li T, Kis O, Zhao Z, Spreafico A, Medina TDS, Wang Y, Roulois D, Ettayebi I, Chen Z, Chow S, Murphy T, Arruda A, O'Kane GM, Liu J, Mansour M, McPherson JD, O'Brien C, Leighl N, Bedard PL, Fleshner N, Liu G, Minden MD, Gallinger S, Goldenberg A, Pugh TJ, Hoffman MM, Bratman SV, Hung RJ, De Carvalho DD. Shen SY, et al. Nature. 2018 Nov;563(7732):579-583. doi: 10.1038/s41586-018-0703-0. Epub 2018 Nov 14. Nature. 2018. PMID: 30429608 Free article.
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Kanjanapan Y, Day D, Wang L, Al-Sawaihey H, Abbas E, Namini A, Siu LL, Hansen A, Razak AA, Spreafico A, Leighl N, Joshua AM, Butler MO, Hogg D, Chappell MA, Soultani L, Chow K, Boujos S, Bedard PL. Kanjanapan Y, et al. Cancer. 2019 Apr 15;125(8):1341-1349. doi: 10.1002/cncr.31999. Epub 2019 Feb 15. Cancer. 2019. PMID: 30768786 Free article.
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs.
Hansen AR, Ala-Leppilampi K, McKillop C, Siu LL, Bedard PL, Abdul Razak AR, Spreafico A, Sridhar SS, Leighl N, Butler MO, Hogg D, Sacher A, Oza AM, Al-Agha R, Maurice C, Chan CT, Shapera S, Feld JJ, Nisenbaum R, Webster K, Cella D, Parsons J. Hansen AR, et al. Cancer. 2020 Apr 1;126(7):1550-1558. doi: 10.1002/cncr.32692. Epub 2020 Jan 8. Cancer. 2020. PMID: 31914209 Free article.
Cancer patients' experiences with immune checkpoint modulators: A qualitative study.
Ala-Leppilampi K, Baker NA, McKillop C, Butler MO, Siu LL, Spreafico A, Abdul Razak AR, Joshua AM, Hogg D, Bedard PL, Leighl N, Oza AM, Parsons JA, Hansen AR. Ala-Leppilampi K, et al. Cancer Med. 2020 May;9(9):3015-3022. doi: 10.1002/cam4.2940. Epub 2020 Mar 2. Cancer Med. 2020. PMID: 32119767 Free PMC article.
313 results